CG Oncology CGON Stock Issuance Costs Accrued But Not Yet Paid
Stock Issuance Costs Accrued But Not Yet Paid at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept ck0001991792:StockIssuanceCostsAccruedButNotYetPaid.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's stock issuance costs accrued but not yet paid.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's stock issuance costs accrued but not yet paid?
- CG Oncology (CGON) reported stock issuance costs accrued but not yet paid of $139K in Q1 2026.
- How has CG Oncology's stock issuance costs accrued but not yet paid changed year-over-year?
- CG Oncology's stock issuance costs accrued but not yet paid decreased by 35.3% year-over-year, from $215K to $139K.
- What does stock issuance costs accrued but not yet paid mean?
- This metric tracks the liability for costs associated with issuing equity securities that have been recognized but remain unpaid at the end of the reporting period. It provides visibility into pending cash obligations related to capital market transactions. High levels of accrued issuance costs may indicate upcoming cash outflows that will impact future liquidity.